

Jan TrÅ, st JÅ, rgensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/600591/publications.pdf>

Version: 2024-02-01

56
papers

1,369
citations

361045

20
h-index

344852

36
g-index

57
all docs

57
docs citations

57
times ranked

1678
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. <i>Journal of Cancer</i> , 2012, 3, 137-144.	1.2	219
2	Targeted HER2 Treatment in Advanced Gastric Cancer. <i>Oncology</i> , 2010, 78, 26-33.	0.9	132
3	The value of <i>TOP2A</i> gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. <i>Acta Oncologica</i> , 2008, 47, 725-734.	0.8	101
4	Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects. <i>Frontiers in Oncology</i> , 2014, 4, 105.	1.3	77
5	Companion diagnostics – a tool to improve pharmacotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 482-482.	0.7	57
6	Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 131-133.	1.5	52
7	Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. <i>Trends in Cancer</i> , 2016, 2, 706-712.	3.8	49
8	A challenging drug development process in the era of personalized medicine. <i>Drug Discovery Today</i> , 2011, 16, 891-897.	3.2	44
9	Companion diagnostics: the key to personalized medicine. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 153-156.	1.5	41
10	Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. <i>World Journal of Gastroenterology</i> , 2014, 20, 4526.	1.4	40
11	Pharmacodiagnosics and Targeted Therapies – A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer. <i>Oncologist</i> , 2007, 12, 397-405.	1.9	37
12	Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. <i>Oncologist</i> , 2019, 24, e432-e440.	1.9	36
13	Companion Diagnostics in Oncology - Current Status and Future Aspects. <i>Oncology</i> , 2013, 85, 59-68.	0.9	32
14	The current landscape of the FDA approved companion diagnostics. <i>Translational Oncology</i> , 2021, 14, 101063.	1.7	32
15	Clinical application of companion diagnostics. <i>Trends in Molecular Medicine</i> , 2015, 21, 405-407.	3.5	31
16	Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 999-1008.	2.3	31
17	New Era of Personalized Medicine: A 10-Year Anniversary. <i>Oncologist</i> , 2009, 14, 557-558.	1.9	30
18	A paradigm shift in biomarker guided oncology drug development. <i>Annals of Translational Medicine</i> , 2019, 7, 148-148.	0.7	25

#	ARTICLE	IF	CITATIONS
19	Are we approaching the post-blockbuster era? Pharmacodiagnosics and rational drug development. Expert Review of Molecular Diagnostics, 2008, 8, 689-695.	1.5	24
20	Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. Acta Oncologica, 2008, 47, 1054-1061.	0.8	21
21	Improvement of Patient Convenience in Treatment with Growth Hormone. Journal of Pediatric Endocrinology and Metabolism, 1994, 7, 175-80.	0.4	20
22	A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer. Frontiers in Oncology, 2021, 11, 676939.	1.3	20
23	From blockbuster medicine to personalized medicine. Personalized Medicine, 2008, 5, 55-63.	0.8	19
24	High Concordance Between Two Companion Diagnostics Tests. American Journal of Clinical Pathology, 2011, 136, 145-151.	0.4	19
25	The importance of predictive biomarkers in oncology drug development. Expert Review of Molecular Diagnostics, 2016, 16, 807-809.	1.5	14
26	Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers, 2022, 14, 2150.	1.7	14
27	Oncology drug-companion diagnostic combinations. Cancer Treatment and Research Communications, 2021, 29, 100492.	0.7	13
28	Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx, (Dako Omnis) assay. Pathology Research and Practice, 2016, 212, 735-742.	1.0	11
29	Drug-Diagnostic Co-Development in Cancer. Pharmaceutical Medicine, 2010, 24, 363-375.	1.0	10
30	Companion Diagnostics and the Drug-Diagnostic Codevelopment Model. Drug Development Research, 2012, 73, 390-397.	1.4	10
31	Site-agnostic biomarker-guided oncology drug development. Expert Review of Molecular Diagnostics, 2020, 20, 583-592.	1.5	10
32	Predictive biomarkers and clinical evidence. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 642-648.	1.2	9
33	Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer. Journal of Cancer, 2017, 8, 1517-1524.	1.2	8
34	Companion and complementary diagnostics: an important treatment decision tool in precision medicine. Expert Review of Molecular Diagnostics, 2020, 20, 557-559.	1.5	8
35	The new era of personalized medicine: 10 years later. Personalized Medicine, 2009, 6, 423-428.	0.8	7
36	When biomarkers define a drug indication. Expert Review of Molecular Diagnostics, 2018, 18, 315-317.	1.5	7

#	ARTICLE	IF	CITATIONS
37	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S95-S99.	1.3	7
38	A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects. <i>Acta Radiologica</i> , 2012, 53, 707-713.	0.5	6
39	PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC. <i>Chinese Clinical Oncology</i> , 2020, 9, 60-60.	0.4	5
40	Detection of MET amplification in gastroesophageal tumor specimens using IQFISH. <i>Annals of Translational Medicine</i> , 2017, 5, 458-458.	0.7	5
41	The Development of the HercepTest™ from Bench to Bedside. , 2019, , 43-60.		5
42	Analysis of HER2 status in gastroesophageal tumor specimens using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay. <i>Histology and Histopathology</i> , 2016, 31, 1327-35.	0.5	5
43	Drug-Diagnostics Co-Development in Oncology. <i>Frontiers in Oncology</i> , 2014, 4, 208.	1.3	4
44	An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 445-454.	1.5	4
45	Development, production and pharmacodynamics of human growth hormone. <i>Indian Journal of Pediatrics</i> , 1991, 58, 23-32.	0.3	2
46	Companion Diagnostics: From Biomarkers to Diagnostics. , 2017, , 530-545.		2
47	MET deletion is a frequent event in gastric/gastroesophageal junction/esophageal cancer: a cross-sectional analysis of gene status and signal distribution in 1,580 patients. <i>Annals of Translational Medicine</i> , 2021, 9, 225-225.	0.7	2
48	The ESMO Precision Medicine Glossary. <i>Annals of Oncology</i> , 2018, 29, 781-782.	0.6	1
49	An Introduction to Companion and Complementary Diagnostics. , 2019, , 1-10.		1
50	Regulatory Requirements for Companion Diagnostics and Drug-Diagnostic Codevelopment in the United States. , 2019, , 307-318.		1
51	Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
52	The Drug-Diagnostic Codevelopment Model. , 2019, , 11-25.		0
53	Companion and complementary diagnostics: A key to precision medicine. , 2021, , 97-107.		0
54	<i>HER2</i> amplification and gene signal distribution in gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15600-e15600.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Developing Molecular Diagnostics in Cancer. , 2019, , 1-20.		0
56	Pharmacodiagnosics and Personalized Medicine in Cancer. , 2019, , 325-344.		0